How do REGN and SGEN differ fundamentally?

Regeneron is a fully independent large biotech with three blockbuster products (Dupixent, EYLEA, Libtayo) and an internal research platform generating pipeline. Seagen was an ADC oncology specialist whose entire portfolio has been acquired by Pfizer. Regeneron continues as a public company; Seagen does not. All SGEN investors received Pfizer shares as acquisition consideration.

What metrics matter most when comparing REGN and SGEN?

For Regeneron, track Dupixent global revenue growth, new Dupixent indication approvals, EYLEA HD uptake vs original EYLEA biosimilar competition, and Libtayo oncology quarterly revenue. For Seagen's pipeline within Pfizer, track Pfizer's oncology revenue segment and Padcev, Adcetris, and Tivdak combined revenue within Pfizer's quarterly reports.

Which is better for long-term investors — REGN or SGEN?

Regeneron is one of the highest-quality long-term biotech investments available — Dupixent's rare blockbuster growth trajectory and VelociSuite pipeline create durable long-term value. Seagen's assets within Pfizer may generate significant long-term value for Pfizer shareholders through ADC oncology expansion. Long-term biotech investors choosing between these companies should compare Regeneron vs Pfizer, not Regeneron vs a now-private company.

brimindinvest.com / compare / regn-vs-sgenLIVE

REGN

Regeneron Pharmaceuticals, Inc. · Healthcare

$609.94

-3.23% this month

VERSUS

⟷

COMPARE

SGEN

Seagen Inc. (acquired by Pfizer 2023) · Healthcare

N/A

N/A this month

Scoreboard verdict

Across AI score, momentum, valuation, upside, operating margin

REGN

0

SGEN

0

MIXED SETUP

Comparison scoreboard

MIXED SETUP

AI Score

REGN 42.1

SGEN N/A

1Y Return

REGN +19.86%

SGEN N/A

Fwd P/E

REGN 11.38

SGEN N/A

Target Up.

REGN +36.13%

SGEN N/A

Op. Margin

REGN 20.66%

SGEN N/A

Metrics last refreshed: 6/20/2026

Quick take

REGN vs SGEN Stock Comparison: AI Score, Valuation, Performance and Upside

Regeneron and Seagen represent two very different biotech business models. Regeneron is an independent, fully integrated biopharma company with blockbuster biologics (Dupixent) and a proprietary research platform. Seagen was an ADC oncology specialist now part of Pfizer. Regeneron remains one of the most exciting large-cap biopharma investment opportunities with Dupixent still growing and multiple upcoming indication approvals. Seagen, as Pfizer's oncology asset, is now only accessible by investing in Pfizer.

REGN vs SGEN is the fully independent biotech with Dupixent as one of the world's fastest-growing biologics and proprietary VelociSuite antibody platform (Regeneron) versus Seagen's ADC oncology portfolio now integrated into Pfizer following the $43B acquisition — Regeneron remains a high-quality public company; Seagen is now accessible only through Pfizer.

Live analysis · updated 6/20/2026

REGN and SGEN are closely matched — they split the tracked metrics evenly.

Normalized 1Y performance

REGN

SGEN

Not enough data to chart yet.

Recent returns

REGN

SGEN

Analyst price targets & sentiment

REGN · 23 analysts

STRONG BUYHOLDSTRONG SELL

Buy (1.7/5.0)

Price target range

analyst low$535.00
analyst high$950.00
analyst mean$833.31
current price$609.94

+36.1% upside to analyst mean

SGEN

Price target data unavailable

N/A

Who should consider this stock?

REGN may suit investors who:

→prefer the large independent biotech with Dupixent's rare 20%+ revenue growth at $14B+ scale and multiple additional indication approvals still ahead
→value Regeneron's VelociSuite proprietary antibody discovery platform generating a deep pipeline without partnership dependency
→want the highest-quality biotech investment where financial independence, blockbuster products, and pipeline breadth create compounding advantages
→are comfortable with EYLEA biosimilar transition risk, eventual Dupixent patent management, and atopic dermatitis competition from Rinvoq and JAK inhibitors

SGEN note for investors:

→Seagen is no longer an independent public company — it was acquired by Pfizer in December 2023 for $43B ($229/share)
→Investors interested in Seagen's ADC portfolio (Padcev, Adcetris, Tivdak, Tukysa) should invest in Pfizer (PFE) which now operates Seagen's pipeline
→ADC oncology is a high-priority growth area for Pfizer — Seagen's assets are a key component of Pfizer's oncology post-COVID revenue recovery strategy
→The SGEN comparison page may be outdated — verify current ticker status before investing in any security labeled SGEN

Performance & AI score

Metric	REGN	SGEN
AI score	42.1	N/A
AI rank	#882	N/A
Latest close	$609.94	N/A
1M return	-3.23%	N/A
6M return	-18.65%	N/A
1Y return	+19.86%	N/A

$10,000 invested — hypothetical growth (dividends reinvested)

How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?

Period	REGN	SGEN
1Y ago	$11.88K (+18.8%) started 2025-06-18	N/A
5Y ago	$11.46K (+14.6%) started 2021-06-21	N/A
10Y ago	$17.37K (+73.7%) started 2016-06-20	N/A

Hypothetical — past performance does not guarantee future results.

Valuation & upside potential

Metric	REGN	SGEN
Market cap	$64.18B	N/A
Trailing P/E	14.95	N/A
Forward P/E	11.38	N/A
Price/Sales	3.78	19.98
EV/Revenue	3.77	N/A
Analyst target	$833.31	N/A
Target upside	+36.13%	N/A

Growth, profitability & risk

Metric	REGN	SGEN
Revenue growth	19.00%	N/A
Earnings growth	-7.20%	N/A
EPS growth	-7.20%	N/A
FCF margin	+21.94%	N/A
Operating margin	20.66%	N/A
Profit margin	29.65%	N/A
ROIC proxy	14.55%	N/A
Return on equity	14.55%	N/A
Dividend yield	0.61%	N/A
Beta	0.24	0.44
Debt/equity	8.61	N/A
Current ratio	3.56	N/A
Quick ratio	2.84	N/A

Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot

REGN max drawdown26.05%

SGEN max drawdownN/A

REGN max wkly drop12.87%

SGEN max wkly dropN/A

5Y risk snapshot

REGN max drawdown59.69%

SGEN max drawdownN/A

REGN max wkly drop20.21%

SGEN max wkly dropN/A

10Y risk snapshot

REGN max drawdown59.69%

SGEN max drawdownN/A

REGN max wkly drop20.21%

SGEN max wkly dropN/A

Performance metrics by period

Period	Metric	REGN	SGEN
1Y	Growth	+18.76%	N/A
	CAGR	+18.79%	N/A
	Sharpe ratio	0.55	N/A
	Max drawdown	26.05%	N/A
	Max daily drop	9.82%	N/A
	Max wkly drop	12.87%	N/A
5Y	Growth	+14.48%	N/A
	CAGR	+2.75%	N/A
	Sharpe ratio	0.10	N/A
	Max drawdown	59.69%	N/A
	Max daily drop	19.01%	N/A
	Max wkly drop	20.21%	N/A
10Y	Growth	+73.43%	N/A
	CAGR	+5.66%	N/A
	Sharpe ratio	0.19	N/A
	Max drawdown	59.69%	N/A
	Max daily drop	19.01%	N/A
	Max wkly drop	20.21%	N/A

Business comparison

Category	REGN	SGEN
Company	Regeneron Pharmaceuticals, Inc.	Seagen Inc. (acquired by Pfizer 2023)
Sector	Healthcare	Healthcare
Industry	Biotechnology	N/A
Core business	Regeneron is a fully integrated biopharma company with three blockbuster drugs: Dupixent (IL-4/IL-13 biologic for atopic dermatitis, asthma, and expanding indications), EYLEA HD (intravitreal VEGF inhibitor for wet AMD), and Libtayo (PD-1 cancer immunotherapy). Regeneron's proprietary VelociSuite research technologies enable faster antibody and multi-specific discovery. Dupixent is one of the world's most important biologic drugs — growing 20%+ with new indications approved annually across atopic dermatitis, asthma, COPD, and eosinophilic esophagitis.	Seagen was a pioneering antibody-drug conjugate (ADC) oncology company acquired by Pfizer for $43B in 2023. Seagen's approved ADC portfolio includes Padcev (bladder cancer), Adcetris (Hodgkin lymphoma, T-cell lymphoma), Tivdak (cervical cancer), and Tukysa (HER2+ breast cancer). ADCs attach cytotoxic (cell-killing) agents to antibody targeting systems to deliver chemotherapy specifically to cancer cells while sparing healthy tissue. Seagen was acquired because its ADC platform and multiple approved oncology drugs made it one of the most valuable independent biotech companies. Note: SGEN stock is no longer publicly traded — it was acquired by Pfizer.
Investor focus	Investors track Dupixent US and global sales, EYLEA HD (higher-dose formulation) penetration vs biosimilar EYLEA pressure, Libtayo oncology expansion, and the next indication approval for Dupixent.	Since acquisition, Seagen operates as part of Pfizer's oncology division — investors tracking Seagen's portfolio should monitor Pfizer's oncology segment revenue instead.

REGN strengths

→Dupixent is one of the most successful biologic drugs in pharmaceutical history — growing to $14B+ annual revenue with multiple additional indication approvals still pending in allergic/inflammatory diseases
→Proprietary VelociSuite antibody discovery platform enables faster generation of high-quality antibody drug candidates than conventional approaches
→Financially independent from partnerships — unlike many biotechs, Regeneron is fully self-funded with strong cash generation from existing products

SGEN strengths

→ADC technology pioneer with 4 approved oncology drugs across different cancer indications — the broadest approved ADC portfolio in the industry at acquisition
→Padcev (enfortumab vedotin) in bladder cancer achieved first-line regulatory approval — a major commercial expansion with EV+Keytruda combination therapy
→ADC platform expertise: Seagen's proprietary linker-payload technology is applicable across many cancer types — pipeline extends well beyond approved drugs

Risks to watch — REGN

→EYLEA original formulation faces biosimilar competition — Regeneron must transition patients to EYLEA HD to maintain franchise revenue
→Dupixent patent cliff is eventually coming — protection needs to be defended through product lifecycle management and indication expansion
→Competition in atopic dermatitis (AbbVie's Rinvoq, Lilly's Lebrikizumab) and asthma (GSK's Nucala) markets where Dupixent operates

Risks to watch — SGEN

→SGEN is no longer an independent public company — Pfizer acquired it in 2023 for $43B per share; investing in Seagen's pipeline now means investing in Pfizer
→ADC competition has increased dramatically since Seagen's acquisition — every major pharma now has an ADC program, reducing Seagen's competitive differentiation within Pfizer
→Pfizer integration: Seagen's culture and pipeline management within the Pfizer organization is a key execution risk

Frequently asked questions

Seagen is no longer a publicly traded company — it was acquired by Pfizer in 2023. Regeneron is an outstanding independent biopharma investment with Dupixent still in its growth phase and multiple indication expansions ahead. For biotech quality, Regeneron is the clear choice; for Seagen's ADC oncology assets, invest in Pfizer which acquired them.

AI Prediction SignalNext 5 trading days

Members only

REGN

+2.8%BUY

SGEN

+1.1%HOLD

Start Free Trial Log in

ML model trained on historical prices · 14-day free trial · No credit card required

Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Start Free Trial Read Investing Guides

Related comparisons

REGN vs BIIB

Which Biotech Stock Is Better?

VRTX vs REGN

Which Specialty Biotech Wins?

BIIB vs REGN

Alzheimer's Drug vs Dupixent Blockbuster

MRNA vs RXRX

mRNA Pioneer vs AI Drug Discovery

REGN vs VRTX

Blockbuster Biologics vs CF Monopoly

BIIB vs GILD

Neurology vs Antiviral & Oncology Biologics